“有市场、无产品、缺指南”!中国生物制药回应为何牵手Cipla,到印度、南非等7个新兴市场卖抗癌药

每日经济新闻
Sep 01

中国生物制药公司的出海第一站,一定是欧美吗?  8月31日,中国生物制药(HK01177)宣布旗下子公司正大天晴与印度跨国药企西普拉(Cipla)就Rolditamig Deuderuxtecan(研发代号:TQB2102)订立独家授权与供应协议,授予后者在印度、南非及其他共计7个高增长新兴市场国家开发及商业化TQB2102的独家权益。  这一交易打破了业内关于创新药出海的刻板印象。过去,行业普遍...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10